藥物成份

共有 21647 個藥物成份

This product is prepared from human blood with chemicals and preservatives added. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human plasma, with added purified biochemicals and preservatives.\nThis products is provided in lyophilized form for increased stability.

關聯藥證數量
1

This product is prepared from human serum and preservatives.

關聯藥證數量
1

This product is prepared from human serum and preservatives. The control is provided in liquid form.

關聯藥證數量
1

This product is prepared from human serum to which purified biochemical material (tissue extracts of human and animal origin), chemicals, drugs, preservatives and stabilizers have been added. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human serum with added constituents of animal origin, chemicals, preservatives and stabilizers. The control is provided in liquid from for convenience.

關聯藥證數量
1

This product is prepared from human serum with added constituents of animal origin, chemicals, preservatives, and stabilizers.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human and animal origin and preservatives. The mean values were derived from replicate analysis and are specific for the lot of product.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human and animal origin, chemical, stabilizers and preservatives.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human and animal origin, preservatives and stabilizers. The control is provided in liquid for convenience.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human and animal origin, preservatives and stabilizers. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human and animal origin, stabilizers, and preservatives. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human serum with added constituents of human origin, stabilizers, and preservatives.\nThe mean values and the range of analytes are specific for each lot of the product.

關聯藥證數量
1

This product is prepared from human serum with added preservatives, chemicals and constituents of animal origin. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human serum with added preservatives, stabilizers, selected benzodiazepines, tricyclics, other antidepressants and constituents of animal origin. The control is provided in lyophilized form.

關聯藥證數量
1

This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human serum with added serum protein, constituents of animal origin, stabilizers and preservatives. The control is provided in lyophilized from for increased stability.

關聯藥證數量
1

This product is prepared from human urine with added constituents of human origin, chemicals, preservatives and stabilizers. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from human urine with added drugs of abuse and metabolites of drugs of abuse, preservatives, stabilizers and constituents of animal origin. The control is provided in liquid from for convenience.

關聯藥證數量
1

This product is prepared from human urine with added drugs of abuse, metabolites of drugs of abuse, preservatives, stabilizers or constituents\nof animal origin. The values of the analytes are specific for each lot of the product.

關聯藥證數量
1

This product is prepared from human urine with added human erythrocytes, simulated leukocyte, constituents of animal origin, chemicals, preservatives and stabilizers. The results were derived from replicate analysis and are specific for the lot of product.

關聯藥證數量
1

This product is prepared from human whole blood and contains abnormal hemoglobins, preservatives and stabilizers. The control is provided in lyophilized form for increased stability.

關聯藥證數量
1

This product is prepared from human whole blood and contains preservatives and stabilizers. The target values were derived from replicate analysis and are specific for the lot of product.

關聯藥證數量
1

This product is prepared from human whole blood, with added chemicals and stabilizers. The control is provided in lyophilized form for increased stability.

關聯藥證數量
1

This product is prepared from pre-diluted human serum with added constituents of animal and preservatives. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from pre-diluted human serum with added constituents of animal origin and preservatives.

關聯藥證數量
1

This product is prepared from pre-diluted human serum with added constituents of animal origin and preservatives. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from processed human plasma or serum reactive for Immunoglobulin M antibodies to Hepatitis A Virus (HAV-IgM), Immunoglobulin M antibodies to Hepatitis B core Antigen (HBc-IgM), Hepatitis B e Antigen (HBeAg) and total antibody to Hepatitis A Virus (anti-HAV), proteins from human sources, antimicrobial agents as preservative, and stabilizers. Human source materials reactive for viral hepatitis makers have been treated to inactivate infectious agents.

關聯藥證數量
1

This product is prepared from processed human plasma or serum reactive for antibodies to Hepatitis B Surface Antigen (anti-HBs) and antibodies to Hepatitis A Virus (anti-HAV), proteins from human sources, antimicrobial agents as preservative, and stabilizers. Human source materials reactive for anti-HBs markers have been treated to inactivate infectious agents.

關聯藥證數量
1

This product is prepared from processed human plasma or serum reactive to anti-HBe, proteins from human sources, antimicrobial agents as preservative, and stabilizers. Human source materials reactive for viral hepatitis markers have been treated to inactivate infectious agents.

關聯藥證數量
1

This product is prepared from processed human plasma with added constituents of human and animal origin, and preservatives. The control is provided in liquid form for convenience.

關聯藥證數量
1

This product is prepared from processed human plasma with added constituents of human and animal origin, chemicals, preservatives and stabilizers. The mean values were derived from replicated analyses and are specific for the lot of product.

關聯藥證數量
1

This product is suspension of stabilized lysable human erythrocytes with added constituents of animal origins, platelet components and fixed red cells (to simulate white cells) in a medium containing preservatives.

關聯藥證數量
1

This product is the Na+: 14mmol/L, K+: 0.40mmol/L and Cl-: 10mmol/L mixture

關聯藥證數量
1

This product was designed for use with in vitro assay procedures for purposes of monitoring assay performance and maintaining quality assurance. This product is prepared from processed human plasma or serum and other human sourced proteins. Source materials have been chemically treated and processed to eliminate unwanted components and to ensure stability of the final product. Each lot of material is designed to be non-reactive when analyzed in the same manner as unknown specimens, according to the instructions supplied by the manufacturer of the test kit being used.

關聯藥證數量
1

This product was designed for use with in vitro assay procedures for purposes of monitoring assay performance and maintaining quality assurance. This product is prepared from processed human plasma or serum and other mammalian sourced proteins. Source materials have been chemically treated and processed to eliminate unwanted components and to ensure stability of the final product.

關聯藥證數量
1

Three specially selected TB recombinant proteins.

關聯藥證數量
1

Three specimens: GH2-04 through GH2-06

關聯藥證數量
1

Threonine (L-Threonine), when dried, contains not less than 98.5% and not more than 101.0% of L-Threonine (C4H9NO3).

關聯藥證數量
1

Threonine contains not more than 98.5% and not more than 101.5% of C4H9NO3, as L-threonine, calculated on the dried basis.

關聯藥證數量
1

Thrombin Reagent-Contains lyophilized, bovine thrombin (approximatly 100 NIH units per ml) with stabilizers and buffer.\nFibrinogen Calibration Reference-Contains lyophilized, human plasma, stabilizers, and buffer.\nOwrens Veronal Buffer-Contains 0.028M Sodium Barbital pH 7.40+-0.05.

關聯藥證數量
1

Thrombin: Lyophilized bovine thrombin with an approximate concentration of 12 NIH units per mL after reconstitution.Substrate: Lyophilized chromogenic substrate, EtM-Spro Arg-pNA, AcOH, approximately 1.4 μl per mL after reconstitution.Buffer: Substrate specific solvent containing heparin. Contains less than 1g/L sodium azide as a preservative.

關聯藥證數量
1

Thrombin: Lyophilized bovine thrombin with an approximate concentration of 12 NIH units per mL after reconstitution.\nSubstrate: Lyophilized chromogenic substrate, EtM-Spro Arg-pNA, AcOH, approximately 1.4 ul per mL after reconstitution.\nBuffer: Substrate specific solvent containing heparin. Contains less than 1g/L sodium azide as a preservative.

關聯藥證數量
1

Thrombin試劑(測試卡片)：Bovine thrombin 0.8NIHU/1 test批號卡片

關聯藥證數量
1

Thrombin：冷凍乾燥牛 thrombin、heparin、aprotinin。 Substrate Reagent：冷凍乾燥Tosylglycyl-Prolyl-Larginyl-5-amino-2-nitrobenzoic acid-isopropylamide (Tos-Gly-Pro-Arg-ANBA-IPA) 4 mmol/L。 Buffer Solution：Tris (100 mmol/L), NaCl (8.7 g/L), pH 8.2 保存劑：Sodium azide (<1 g/L)

關聯藥證數量
1

Thyroglobulin Bead Pack (L2TY12):\nBeads, coated with anti-ligand.\nThyroglobulin Reagent Wedge (L2TYA2):\nligand-labeled anti-thyroglobulin murine monoclonal antibody and alkaline phosphatase (bovine calf intestine) conjugated to sheep polyclonal anti-thyroglobulin antibody in buffer\nThyroglobulin Adjustors (LTYL, LTYH):\nLow and High of lyophilized thyroglobulin in a nonhuman serum matrix.\n

關聯藥證數量
1

Thyroid Uptake Bead Pack (L2TU12) :\ncoated with monoclonal murine anti-T3.\nThyroid Uptake Reagent Wedge (L2TUA2) :\nalkaline phosphatase (bovine calf intestine)-labled T3 and unlabeled T3 in buffer.\nThyroid Uptake Adjustor (LTUL) :\nprocessed human serum.\n

關聯藥證數量
1

Thyroid Uptake Reagent:R1a:Paramagnetic particles coated with goat anti-mouse IgG suspended in TRIS buffered saline, with surfactant, bovine serum albumin(BSA)。R1b:Mouse monoclonal antibody to thyroxine in TRIS buffered saline, with surfactant, protein(aves, murine, goat)。R1c:Thyroxine-alkaline phosphatase(bovine) conjugate and thyroxine in TRIS buffered saline, with surfactant, BSA。Thyroid Uptake Calibrator:S0:Lyophilized human serum. Recostitute each vial with 1.0 mL distilled water using a Class A volumetric pipet. Allow to equilibrate for a minimum of 30 minutes while being gently mixed on a rocker or rotator。處方變更為：空白。

關聯藥證數量
1

Thyroid contains not less than 90.0% and not more than 110.0% each of the labeled amounts of levothyroxine (C15H11I4NO4) and liothyronine (C15H12I3NO4), calculated on the dried basis.

關聯藥證數量
1

Tiaprofenic Acid contains not less than 99.0% and not more than 101.0% of C14H12O3S, calculated on dried substance.

關聯藥證數量
1

Tiaprofenic acid contains not less than 99.0% and not more than the equivalent of 101.0% of (2RS)-2-(5-benzoylthiophen-2-yl)propanoic acid, calculated with reference to the dried substance.

關聯藥證數量
1

Tiaprofenic acid, 99.0-101.0%(by acidmetry)

關聯藥證數量
1

Ticagrelor not less than 98.0% and not more than 102.0% of C23H28F2N6O4S calculated on dried basis.

關聯藥證數量
1

Ticlopidine Hydrochloride 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride. Content: 99.0 per cent to 101.0 per cent (anhydrous substance)

關聯藥證數量
1

Ticlopidine Hydrochloride contains not less than 99.0% and not more than 101.0% of C14H14ClNSO？HCl, calculated with reference to the dried basis.

關聯藥證數量
1

Ticlopidine Hydrochloride contains not less than 99.0% and not more than 101.0% of C14H14ClNS‧HCl, calculated on the dried basis.

關聯藥證數量
1

Ticlopidine Hydrochloride contains not less than 99.0% and not more than 101.0% of C14H15Cl2NS, Calculated on the dried basis.

關聯藥證數量
1

Ticlopidine Hydrochloride contains not less than 99.0% and not more than 101.0% of C14H15Cl2NS, calculated on the anhydrous substance.

關聯藥證數量
1

Ticlopidine Hydrochloride contains not less than 99.0% and not more than 101.0% of C14H15Cl2NS, calculated with anhydrous substance.

關聯藥證數量
1

Ticlopidine hydrochloride contains not less than 99.0% and not more than the equivalent of 101.0% of C14H15Cl2NS, calculated with reference on the anhydrous substance.

關聯藥證數量
1

Tigecycline Between 97.0% and 102.0% on anhydrous.

關聯藥證數量
1

Tigecycline 0.016-256 μg/mL。變更規格為：空白。

關聯藥證數量
1

Tigecycline contains not less than 98.0 percent and not more than 102.0 percent of C29H39N5O8, calculated on the anhydrous, solvent-free basis.

關聯藥證數量
1

Timolol Maleate contains not less than 98.0% and not more than 101.0% of C13H24N4O3S‧C4H4O4，calculated on the dried basis.

關聯藥證數量
1

Timolol Maleate contains not less than 98.5% and not more than 101.0% of C13H24N4O3S‧C4H4O4, calculated on the dried basis.

關聯藥證數量
1

Tina-quant ％CDT 2nd generation：\nR1 Phosphate buffer： 100 mmol/L, pH 7.8；polyethylene glycol：70 g/L；\nR2 Anti-human transferrin antibody (rabbit)： titer-dependent；phosphate buffer： 100 mmol/L, pH 7.8；polyethylene glycol：40 g/L；\n\n％CDT Separation Kit 2nd generation：\nR1 Iron(III) chloride： 0.18 mmol/L ; BIS-TRIS buffer： 20 mmol/L, pH6.5;\nR2 BIS-TRIS buffer： 20 mmol/L, pH6.2; sodium chloride≧0.6 g/L;\n

關聯藥證數量
1

Tinidazole contains not less than 98.0 percent and not more than 101.0 percent of C8H13N3O4S, calculated on the dried basis.

關聯藥證數量
1

Tinidazole contains not less than 98.0% and not more than 101.0% of C8H13N3O4S (dried substance).

關聯藥證數量
1

Tinidazole contains not less than 98.0% and not more than 101.0% of C8H13N3O4S, calculated on the dried substance.

關聯藥證數量
1

Tio2

關聯藥證數量
1

Tioconazole contains not less than 97.0 and not more than 103.0% of C16H13Cl3N2OS.

關聯藥證數量
1

Tipepidine Hibenzate contains not less than 98.5% and not more than 101.0% of C15H17NS2？C14H10O4, calculated on the dried basis.

關聯藥證數量
1

Tipepidine Hibenzate,when dried,contains not less than 98.5% of C15H17NS2C14H10O4

關聯藥證數量
1

Tirabrutinib Hydrochloride

關聯藥證數量
1

Tirbanibulin

關聯藥證數量
1

Tisagenlecleucel (CTL019 cells)

關聯藥證數量
1

Tissue Substrate Slides: Each slide well contains a fixed cryostat section of rat tissue. Substrate slides included in the following FLUORO-KITS are: Cat. No. Substrate Slide 1741 Rat kidney/stomach (6 well)\nAutoantibody Negative Human Control Serum: Liquid control in dropper vial containing no detectable autoantibodies. Sodium azide, 0.1%, is added as a preservative.\nAutoantibody Positive Human Control Sera: Each liquid control is labeled with a specific antibody. Sodium azide, 0.1%, is added as a preservative. Control sera included in the following FLUORO-KITS are: Cat. No. Positive Control 1740 & 1741CT-3/2 ANA, AMA, ASMA\nFluorescent Antibody Conjugate: Goat antihuman immunoglobulin conjugated with fluorescein isothiocyanate (FITC). Sodium azide, 0.1%, is added as a preservative.\n

關聯藥證數量
1

Tissue Substrate Slides:Each slide well contains a fixed cryostat section of rat tissue.Autoantibody Negative Human Control Serum:Liquid control in dropper vial containing no detectable autoantibodies. Autoantibody Positive Human Control Sera:Liquid control is labeled with a specific antibody.Fluorescent Antibody Conjugate: Goat antihuman immunoglobulin conjugated with fluorescein isothiocyanate (FITC).Counterstain:Evans Blue Counterstain is in a dropper vial.PBS: Contains dry granular phosphate buffered saline blend.Mounting Medium:Contains phosphate buffered glycerol.

關聯藥證數量
1

Tizanidine Hydrochloride contains not less than 98% and not more than 102% of C9H8ClN5S HCl, calculated on the dried basis.

關聯藥證數量
1

To reconstitute powdered medium, empty entire contents of container into clean vessel that will hold a final volume of 5.0 liters. Add 5.0 liters of water for A.R.T. Use and mix thoronghly. Add 15.14 mL of 60% sodium Lactate solutin, 10.5 grams sodium Bicarbonate and mix thoroughly.

關聯藥證數量
1

Tobramycin Bead Pack: coated with polyclonal rabbit anti-tobramycin.\nTobramycin Reagent Wedge: containing two reagents: 11.5 mL buffer and 5.5 mL alkaline phosphatase (bovine calf intestine) conjugated to tobramycin, in buffer.\nTobramycin Adjustors: Two vials (Low and High), 2.0 mL each, of tobramycin in a human serum/buffer matrix.\nTherapeutic Drug Sample Diluent: 50 mL concentrated (ready-to-use) drug-free buffer matrix.

關聯藥證數量
1

Tobramycin Particle Reagent: 6.5 mL; Monoclonal anti-Tobramycin Antibody (mouse): 4.8 mL; Tobramycin reaction Buffer: 100.0 mL

關聯藥證數量
1

Tobramycin contains not less than 94.0%~100.0% of C18H37N5O9 (dried substance).

關聯藥證數量
1

Tobramycin contains not less than 97.0% and not more than 102.0% of C18H37N5O9, calculated on the anhydrous substance.

關聯藥證數量
1

Tobrmycin in human serum

關聯藥證數量
1

Tocopherol Nicotinate contains not less than 96.0% of nicotinic acid dl-α-tocopherol (C35H53NO3).

關聯藥證數量
1

Tofacitinib Citrate contains not less than 98.0% and not more than 102.0% of C16H20N6O‧C6H8O7, calculated on dried basis.

關聯藥證數量
1

Tofacitinib Citrate contains not less than 98.0% and not more than 102.0% of C22H28N6O8, calculated on the anhydrous substance.

關聯藥證數量
1

Tofacitinib Citrate not less than 98.5% of C16H20N6O．C6H8O7, calculated on anhydrous substance.

關聯藥證數量
1

Tofacitinib citrate contents not less than 98.0% and not more than 102.0% of C16H20N6O．C6H8O7, calculated on the anhydrous basis.

關聯藥證數量
1

Tolnaftate, USP Not less than 98.0 percent and not more than 102.0 percent of C19H17NOS, calculated on the dried basis.

關聯藥證數量
1

Tolterodine L-Tartrate contains not less than 98.0% and not more than 102.0% of C26H37NO7 calculated on the dried basis.

關聯藥證數量
1

Tolterodine Tartrate contains not less than 97.0% and not more than 103.0% of C26H37NO7

關聯藥證數量
1

Tolterodine Tartrate contains not less than 98.0% and not more than 102.0% of C26H37NO7, calculated on anhydrous basis.

關聯藥證數量
1

Tolterodine Tartrate contains not less than 98.0% and not more than 102.0% of C26H37NO7, calculated on dried basis.

關聯藥證數量
1

Tolterodine Tartrate contains not less than 99.0% and not more than 101.0% of C26H37NO7, calculated on anhydrous substance.

關聯藥證數量
1

Topiramate contains not less than 98.0 percent and not more than 102.0 percent of C12H21NO8S, calculated on the dried basis.

關聯藥證數量
1

Topiramate contains not less than 98.0 percent and not more than 102.0% of percent of C12H21NO8S, calculated on the anhydrous basis.

關聯藥證數量
1

Topotecan Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C23H23N3O5.HCl calculated on the anhydrate basis.

關聯藥證數量
1

Total ACP:\nCitrate buffer (pH 4.8) 140 mmol/l;\n1-Napthyl Phosphate 11 mmol/l;\nFast red TR salt 0.6 mmol/l;\nPentanediol 210 mmol/l;\nNon-Prostatic ACP:\nTartrate 125 mmol/l;\nCitrate buffer (pH 4.8) 140 mmol/l;\n1-Napthyl Phosphate 11 mmol/l;\nFast Red TR salt 0.6 mmol/l;\nPentanediol 210 mmol/l.

關聯藥證數量
1